NVL2: A Potential Drug Target and Biomarker for Diseases (G4931)

Target Name: NVL

NCBI ID: G4931

Content of Review Report on NVL Target / Biomarker

NVL

NVL2: A Potential Drug Target and Biomarker for Diseases

NVL (NVL2), a novel protein that belongs to the NAD+-dependent protein kinase family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. NVL2 is a key regulator of cellular processes that are critical for the survival and growth of cells, including cell division, apoptosis, and inflammation.

The NAD+-dependent protein kinase family is a growing area of 鈥嬧?媟esearch, with numerous studies showing that these enzymes play important roles in a wide range of cellular processes. NVL2 is a member of this family and is involved in the regulation of various cellular processes, including cell growth, differentiation, and stress responses.

One of the key functions of NVL2 is its role in regulating cell division. NVL2 is known to play a role in the regulation of cell cycle progression, including the G1/S transition and the G0/G1 transition. This is important for the regulation of cell growth and the development of cancer.

NVL2 is also involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. NVL2 has been shown to play a role in the regulation of apoptosis, with studies showing that it promotes the programmed cell death that is necessary for tissue growth and development.

In addition to its role in cell division and apoptosis, NVL2 is also involved in the regulation of inflammation. It has been shown to play a role in the regulation of inflammation and has been linked to various inflammatory diseases, including cancer and neurodegenerative diseases.

As a potential drug target, NVL2 is an attractive target for researchers because of its involvement in multiple cellular processes that are important for the survival and growth of cells. This makes it an attractive target for the development of new treatments for a wide range of diseases.

In addition to its potential as a drug target, NVL2 is also a potential biomarker for various diseases. The regulation of NVL2 activity has been shown to be involved in the development and progression of a wide range of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. This makes NVL2 an attractive candidate for use as a biomarker for these diseases.

Overall, NVL2 is a novel and promising protein that has the potential to be a drug target and biomarker for a wide range of diseases. Further research is needed to fully understand its functions and the potential of its use in the treatment of these diseases.

Protein Name: Nuclear VCP Like

Functions: Participates in the assembly of the telomerase holoenzyme and effecting of telomerase activity via its interaction with TERT (PubMed:22226966). Involved in both early and late stages of the pre-rRNA processing pathways (PubMed:26166824). Spatiotemporally regulates 60S ribosomal subunit biogenesis in the nucleolus (PubMed:15469983, PubMed:16782053, PubMed:29107693, PubMed:26456651). Catalyzes the release of specific assembly factors, such as WDR74, from pre-60S ribosomal particles through the ATPase activity (PubMed:29107693, PubMed:26456651, PubMed:28416111)

The "NVL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NVL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets